As demonstrated in Figure 1(a), expression differences in CUL5 levels between tumor and normal tissues were found in glioblastoma multiforme (GBM), cholangiocarcinoma (CHOL), KIRC, liver hepatocellular carcinoma (LIHC), breast invasive carcinoma (BRCA), stomach adenocarcinoma (STAD), uterine corpus endometrial carcinoma (UTEC), thyroid carcinoma (THCA) (all P < 0.001), esophageal carcinoma, rectum adenocarcinoma (READ), and bladder urothelial carcinoma (all P < 0.05). Here, CUL5 is linked to bladder transitional cell carcinoma.